Advice

Following an abbreviated submission

Mesalazine 800 mg modified release tablet (Asacol) is accepted for use in NHS Scotland for the treatment of mild acute exacerbations of ulcerative colitis.

At the recommended dose of up to 2.4g daily, the 800 mg strength allows halving of the pill burden compared with the 400 mg formulation at no extra cost.

Download detailed advice53KB (PDF)

Download

Medicine details

Medicine name:
mesalazine (Asacol)
SMC ID:
223/05
Indication:
Mild acute exacerbations for ulcerative colitis
Pharmaceutical company
Procter and Gamble
BNF chapter
Gastro-intestinal system
Submission type
Abbreviated
Status
Accepted
Date advice published
11 February 2008